FI91855B - Förfarande för framställning av nya, terapeutiskt användbara, eventuellt -substituerade 4-(kinolin-2-ylmetoxi)-fenylättiksyror och -estrar - Google Patents

Förfarande för framställning av nya, terapeutiskt användbara, eventuellt -substituerade 4-(kinolin-2-ylmetoxi)-fenylättiksyror och -estrar Download PDF

Info

Publication number
FI91855B
FI91855B FI892016A FI892016A FI91855B FI 91855 B FI91855 B FI 91855B FI 892016 A FI892016 A FI 892016A FI 892016 A FI892016 A FI 892016A FI 91855 B FI91855 B FI 91855B
Authority
FI
Finland
Prior art keywords
quinolin
phenyl
ylmethoxy
acid
methyl ester
Prior art date
Application number
FI892016A
Other languages
English (en)
Finnish (fi)
Other versions
FI892016A0 (sv
FI892016A (sv
FI91855C (sv
Inventor
Siegfried Raddatz
Romanis Fruchtmann
Reiner Mueller-Peddinghaus
Christian Kohlsdorfer
Klaus Mohrs
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI892016A0 publication Critical patent/FI892016A0/sv
Publication of FI892016A publication Critical patent/FI892016A/sv
Publication of FI91855B publication Critical patent/FI91855B/sv
Application granted granted Critical
Publication of FI91855C publication Critical patent/FI91855C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (2)

1. Förfarande för framställning av nya, terapeu-tiskt användbara, eventuellt α-substituerade 4-(kinolin-5 2-ylmetoxi)fenylättiksyror och -estrar med den allmänna formeln (I) caxv COgR1 väri R1 är väte, Ci.g-alkyl eller en grupp med formeln 15 -CH2-C02-R3 väri R3 är väte, C^-alkyl eller fenyl-C^-alkyl, 20 och R2 är väte, C^-alkyl, C2.7-alkenyl eller C2_7-alkynyl, samt salter därav, ’ kännetecknat därav; att man t* . [A] omsätter en fenol med den allmänna formeln (II) C02R4 30 väri : R2 betecknar samma som ovan :·!·. och • * ,···. r4 är Cj.g-alkyl eller en grupp med formeln • · # · ·
35 -CH2-C02-Rs • · · * « · • · • · 91855 38 väri R5 är C1_6-alkyl eller fenyl-C^g-alkyl, med en 2-halogenmetylkinolin med formeln (III) 5 (III) väri X är halogen, 10 och vid framställning av en syra förtvälar en ester, eller [B] alkylerar en ester med den allmänna formeln (IV) 00^°Y^ji (IV) H 20 väri R4 betecknar samma som ovan, med en halogenid med den allmänna formeln (V) R6 - X (V) 25 · väri R6 är -alkyl, C2_7-alkenyl eller C2.7-alkynyl och X är halogen, 30 och vid framställning av en syra förtvälar en ester, och eventuellt framställer salter med hjälp av fysiolo-giskt godtagbara syror eller baser.
2. Förfarande enligt patentkravet 1, k ä n n e -35 tecknat därav, att det utförs vid en temperatur av 0 - 150 eC. li
FI892016A 1988-04-29 1989-04-27 Förfarande för framställning av nya, terapeutiskt användbara, eventuellt -substituerade 4-(kinolin-2-ylmetoxi)-fenylättiksyror och -estrar FI91855C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3814504A DE3814504A1 (de) 1988-04-29 1988-04-29 (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3814504 1988-04-29

Publications (4)

Publication Number Publication Date
FI892016A0 FI892016A0 (sv) 1989-04-27
FI892016A FI892016A (sv) 1989-10-30
FI91855B true FI91855B (sv) 1994-05-13
FI91855C FI91855C (sv) 1994-08-25

Family

ID=6353182

Family Applications (1)

Application Number Title Priority Date Filing Date
FI892016A FI91855C (sv) 1988-04-29 1989-04-27 Förfarande för framställning av nya, terapeutiskt användbara, eventuellt -substituerade 4-(kinolin-2-ylmetoxi)-fenylättiksyror och -estrar

Country Status (20)

Country Link
US (1) US4929626A (sv)
EP (1) EP0339416B1 (sv)
JP (1) JPH01313466A (sv)
KR (1) KR900016136A (sv)
CN (1) CN1027068C (sv)
AT (1) ATE89819T1 (sv)
AU (1) AU614358B2 (sv)
CA (1) CA1333803C (sv)
DD (1) DD283811A5 (sv)
DE (2) DE3814504A1 (sv)
DK (1) DK168009B1 (sv)
ES (1) ES2054919T3 (sv)
FI (1) FI91855C (sv)
HU (1) HU205079B (sv)
IE (1) IE62888B1 (sv)
IL (1) IL90052A (sv)
NO (1) NO175149C (sv)
NZ (1) NZ228899A (sv)
PT (1) PT90382B (sv)
ZA (1) ZA893171B (sv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
GB8728051D0 (en) * 1987-12-01 1988-01-06 Leo Pharm Prod Ltd Chemical compounds
DE3900261A1 (de) * 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5102881A (en) * 1988-06-27 1992-04-07 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3927931A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
DE3927930A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate
US5071988A (en) * 1989-10-27 1991-12-10 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
US4996214A (en) * 1990-06-28 1991-02-26 Smithkline Beecham Corporation Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
US5187180A (en) * 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5221678A (en) * 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5266568A (en) * 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
DE4226649A1 (de) * 1992-08-12 1994-02-17 Bayer Ag Neue isobutylsubstituierte Methansulfonyl-chinolylmethoxyphenyl-cycloalkylessigsäureaminole
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4139751A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
US5304563A (en) * 1991-02-22 1994-04-19 Bayer Aktiengesellschaft 2-substituted quinolines, and their use in medicaments
DE4112533A1 (de) * 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
DE4139750A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
DE4219765A1 (de) * 1992-06-17 1993-12-23 Bayer Ag Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate
DE4226519A1 (de) * 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
ES2061406B1 (es) * 1993-05-07 1995-06-01 Uriach & Cia Sa J Nuevos derivados de la 2-(quinolina) con actividad farmacologica.
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
US10080748B2 (en) 2014-02-04 2018-09-25 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
ZA858347B (en) * 1984-10-30 1986-09-24 Usv Pharma Corp Anti-inflammatory/anti-allergic compounds
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines

Also Published As

Publication number Publication date
CN1045777A (zh) 1990-10-03
JPH01313466A (ja) 1989-12-18
ES2054919T3 (es) 1994-08-16
DK168009B1 (da) 1994-01-17
DK208789D0 (da) 1989-04-28
CN1027068C (zh) 1994-12-21
IE62888B1 (en) 1995-03-08
NZ228899A (en) 1991-06-25
KR900016136A (ko) 1990-11-12
CA1333803C (en) 1995-01-03
HU205079B (en) 1992-03-30
AU614358B2 (en) 1991-08-29
HUT50779A (en) 1990-03-28
EP0339416A1 (de) 1989-11-02
IL90052A (en) 1993-07-08
ATE89819T1 (de) 1993-06-15
AU3385289A (en) 1989-11-02
PT90382B (pt) 1994-09-30
DK208789A (da) 1989-10-30
IL90052A0 (en) 1989-12-15
FI892016A0 (sv) 1989-04-27
PT90382A (pt) 1989-11-10
DE3814504A1 (de) 1989-11-09
NO175149B (no) 1994-05-30
IE891402L (en) 1989-10-29
NO891523D0 (no) 1989-04-13
DD283811A5 (de) 1990-10-24
ZA893171B (en) 1989-12-27
NO891523L (no) 1989-10-30
DE58904459D1 (de) 1993-07-01
EP0339416B1 (de) 1993-05-26
FI892016A (sv) 1989-10-30
FI91855C (sv) 1994-08-25
NO175149C (no) 1994-09-07
US4929626A (en) 1990-05-29

Similar Documents

Publication Publication Date Title
FI91855B (sv) Förfarande för framställning av nya, terapeutiskt användbara, eventuellt -substituerade 4-(kinolin-2-ylmetoxi)-fenylättiksyror och -estrar
KR0131202B1 (ko) 치환 4-(퀴놀린-2-일-메톡시)페닐-아세트산 유도체
KR101156277B1 (ko) 효능 있는 항-당뇨성 화합물의 염 및 다형체
EP0233763B1 (en) 2-substituted quinoline dioic acids
US5091392A (en) Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and -cyanamides, processes for their preparation and their use in medicaments
WO2008079427A1 (en) 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
EP0106565A1 (en) Leukotriene antagonists, their production, and compositions containing them
HU209293B (en) Process for producing cyclic substituted (quinolin-2-yl-methoxy)-phenyl acetic acid derivatives and pharmaceutical compositions containing them
RU2066315C1 (ru) Замещенные производные миндальной кислоты и способ их получения
US5597833A (en) Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives
FI73206C (sv) Förfarande för framställning av terapeutiskt användbara alkyltiofenoxi propylaminer.
US7470788B2 (en) Antitumor agents
US4952602A (en) Phenyl benzothiophene hypolipidemic derivatives
CA2084162A1 (en) Quinolylmethoxyphenyl-acetamides
CA2202563A1 (en) New arylacetamides
RU2103261C1 (ru) Изобутилзамещенные амиды метансульфонилхинолилметоксифенилциклоалкилуксусной кислоты или их фармацевтически приемлемые соли
US4663319A (en) 3-(1,3-dithiol-2-ylidene)-2,4-dioxopyrrolidines, -piperidines, and -hexahydroazepines and use thereof against hepatic diseases
JPH01261375A (ja) 置換イミダゾリノン類又はイミダゾリチオン類
US5120744A (en) Substituted (quinolin-2-yl-methoxy)phenylthioureas
JPH0341458B2 (sv)
EP0528957A1 (en) Five-membered ring alkanoic acid leukotriene antagonists
EP0403249A1 (en) Leukotriene antagonists

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: BAYER AKTIENGESELLSCHAFT